文献速递乳腺癌

阿替利珠单抗联合白蛋白紫杉醇一线治疗晚期三阴性乳腺癌:IMpassion130更新疗效结果

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-11-27

IMpassion130是一项随机双盲安慰剂对照3期试验,评估阿替利珠单抗联合白蛋白紫杉醇一线治疗不可切除局部晚期或转移性三阴性乳腺癌。

要点

  • 该阳性结果因预设统计检验层级未能正式检验。

核心结论

  • 第二次中期总生存分析显示意向治疗人群总生存无显著差异,但PD-L1免疫细胞阳性患者中提示有临床意义的总生存获益。
  • 该阳性结果因预设统计检验层级未能正式检验。

研究设计与样本

  • 随机、安慰剂对照、双盲、3期试验,在41个国家246个学术中心和社区肿瘤实践进行。
  • 纳入902例既往未治疗的组织学确诊的局部晚期或转移性三阴性乳腺癌患者,ECOG评分0或1。
  • 按1:1随机分配至阿替利珠单抗840 mg(第1、15天)联合白蛋白紫杉醇100 mg/m2(第1、8、15天)或安慰剂联合白蛋白紫杉醇,每28天为一周期。
  • 随机分层因素包括既往紫杉烷使用、肝转移和肿瘤浸润免疫细胞PD-L1表达。

主要发现

  • 截至2018年9月3日安全性数据,最常见3-4级不良事件为中性粒细胞减少(阿替利珠单抗组38/453[8%] vs 安慰剂组36/437[8%])、周围神经病变(25[6%] vs 12[3%])、中性粒细胞计数降低(22[5%] vs 16[4%])和疲乏(17[4%] vs 15[3%])。
  • 治疗相关死亡:阿替利珠单抗组2例(<1%)(1例阿替利珠单抗相关自身免疫性肝炎,1例白蛋白紫杉醇相关感染性休克),安慰剂组1例(<1%)(肝衰竭)。

关键数值与推荐

  • PD-L1免疫细胞阳性定义为肿瘤浸润免疫细胞PD-L1表达≥1%。
  • 共主要终点为研究者按RECIST 1.1评估的无进展生存和总生存,在意向治疗人群和PD-L1免疫细胞阳性患者中评估。
  • 预设统计检验层级要求意向治疗人群总生存显著差异后,方可正式检验PD-L1免疫细胞阳性亚组的总生存。

临床怎么用

  • 对于PD-L1免疫细胞阳性的转移性三阴性乳腺癌患者,阿替利珠单抗联合白蛋白紫杉醇可作为重要的治疗选择。
  • 意向治疗人群总生存未达显著差异,PD-L1免疫细胞阳性亚组的获益为探索性分析,需结合统计检验层级解读。

局限性

  • PD-L1免疫细胞阳性亚组的总生存获益因预设统计检验层级未能正式检验。
  • 第二次中期分析时意向治疗人群总生存差异未达到统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy in combination with chemotherapy has shown promising efficacy across many different tumour types. We report the prespecified second interim overall survival analysis of the phase 3 IMpassion130 study assessing the efficacy and safety of atezolizumab plus nab-paclitaxel in patients with unresectable, locally advanced or metastatic triple-negative breast cancer. METHODS: In this randomised, placebo-controlled, double-blind, phase 3 trial, done in 246 academic centres and community oncology practices in 41 countries, patients aged 18 years or older, with previously untreated, histologically documented, locally advanced or metastatic triple-negative breast cancer, and Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible. Patients were randomly assigned (1:1) using a permuted block method (block size of four) and an interactive voice-web response system. Randomisation was stratified by previous taxane use, liver metastases, and PD-L1 expression on tumour-infiltrating immune cells. Patients received atezolizumab 840 mg or matching placebo intravenously on day 1 and day 15 of every 28-day cycle and nab-paclitaxel 100 mg/m2 of body surface area intravenously on days 1, 8, and 15 until progression or unacceptable toxicity. Investigators, patients, and the funder were masked to treatment assignment. Coprimary endpoints were investigator-assessed progression-free survival per Response Evaluation Criteria in Solid Tumors version 1.1 and overall survival, assessed in the intention-to-treat population and in patients with PD-L1 immune cell-positive tumours (tumours with ≥1% PD-L1 expression). The final progression-free survival results were previously reported at the first interim overall survival analysis. The prespecified statistical testing hierarchy meant that overall survival in the subgroup of PD-L1 immune cell-positive patients could only be formally tested if overall survival was significantly different between the treatment groups in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02425891. FINDINGS: Between June 23, 2015, and May 24, 2017, 902 patients were enrolled, of whom 451 were randomly assigned to receive atezolizumab plus nab-paclitaxel and 451 were assigned to receive placebo plus nab-paclitaxel (the intention-to-treat population). Six patients from each group did not receive treatment. At the second interim analysis (data cutoff Jan 2, 2019), median follow-up was 18·5 months (IQR 9·6-22·8) in the atezolizumab group and 17·5 months (8·4-22·4) in the placebo group. Median overall survival in the intention-to-treat patients was 21·0 months (95% CI 19·0-22·6) with atezolizumab and 18·7 months (16·9-20·3) with placebo (stratified hazard ratio [HR] 0·86, 95% CI 0·72-1·02, p=0·078). In the exploratory overall survival analysis in patients with PD-L1 immune cell-positive tumours, median overall survival was 25·0 months (95% CI 19·6-30·7) with atezolizumab versus 18·0 months (13·6-20·1) with placebo (stratified HR 0·71, 0·54-0·94]). As of Sept 3, 2018 (the date up to which updated safety data were available), the most common grade 3-4 adverse events were neutropenia (38 [8%] of 453 patients in the atezolizumab group vs 36 [8%] of 437 patients in the placebo group), peripheral neuropathy (25 [6%] vs 12 [3%]), decreased neutrophil count (22 [5%] vs 16 [4%]), and fatigue (17 [4%] vs 15 [3%]). Treatment-related deaths occurred in two (<1%) patients in the atezolizumab group (autoimmune hepatitis related to atezolizumab [n=1] and septic shock related to nab-paclitaxel [n=1]) and one (<1%) patient in the placebo group (hepatic failure). No new treatment-related deaths have been reported since the primary clinical data cutoff date (April 17, 2018). INTERPRETATION: Consistent with the first interim analysis, this second interim overall survival analysis of IMpassion130 indicates no significant difference in overall survival between the treatment groups in the intention-to-treat population but suggests a clinically meaningful overall survival benefit with atezolizumab plus nab-paclitaxel in patients with PD-L1 immune cell-positive disease. However, this positive result could not be formally tested due to the prespecified statistical testing hierarchy. For patients with PD-L1 immune cell-positive metastatic triple-negative breast cancer, atezolizumab plus nab-paclitaxel is an important therapeutic option in a disease with high unmet need. FUNDING: F Hoffmann-La Roche and Genentech.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019. PMID: 31786121. doi:10.1016/S1470-2045(19)30689-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。